09:39 AM EDT, 03/11/2024 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) said Monday that data from its phase 2B trial assessing JNJ-2113 as a treatment for plaque psoriasis showed high rates of skin clearance through 52 weeks.

The efficacy and safety results from week 16 to week 52 were also consistent with data from the Frontier 1 phase 2b trial, Protagonist said.

The drug is being developed by J&J Innovative Medicine under a license and collaboration deal with Protagonist, the company said.

Protagonist shares were rising 3% in early trading Monday.

Price: 31.25, Change: +0.93, Percent Change: +3.07